Biology problem
Late detection by existing imaging techniques.
ctDNA can be detected 9–12 months earlier and creates a window for therapeutic intervention.
Decoupling sensitivity from sequencing depth.
The science behind 2Strands — a proprietary rare variant enrichment technology that makes ultra-deep MRD monitoring accurate, accessible and scalable.
The problem
Recurrence is detectable long before it is detected.
Accessibility problem
ctDNA detection requires ultradeep and broad sequencing.
Not accessible to all labs across different health systems.
Our solution
Enrich the signal first, so depth stops being the price of sensitivity.
Enrich mutant signals
2Strands enriches ctDNA signals before sequencing, enabling ultrasensitive detection of cancer recurrence (MRD) at significantly lower sequencing depth.
Expand access and scalability
By reducing reliance on ultra-deep sequencing, our technology makes post-treatment recurrence detection and serial monitoring more accessible and scalable.
The technology
2Strands allele enrichment platform
Our platform selectively enriches target mutations while depleting non-target alleles.
This reduces sequencing requirements, enables detection of multiple low-frequency mutations, and helps lower cost while delivering best-in-class sensitivity and specificity to make MRD accessible and scalable.
Follow our progress in the newsroom
Funding milestones, accelerator programmes and the latest from our enrichment technology.